Stifel kept Buy rating and USD 63 target for Alkermes stock

Published on 10/08/2026 at 15:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ALKS 7290 reduced ADHD scores by 14.00 and 19.00 points. Alkermes stock costs EUR 36.67 on October 8, 2026 versus EUR 37.02, minus 0.95 percent.

ALKS, IE00B56GVS15, Illustration mit AI erstellt.

Alkermes plc stock (ISIN IE00B56GVS15) was trading at EUR 36.67 at Lang & Schwarz on October 8, 2026 at 3:38 p.m. CEST, while Stifel kept its Buy rating and USD 63.00 price target for Alkermes on October 5, 2026. According to Investing.com, the analyst house cited confidence in Alkermes' clinical pipeline after meetings with management.

ADHD data set the latest milestone

On September 21, 2026, Alkermes reported positive phase 1b results for ALKS 7290, an investigational oral orexin 2 receptor agonist for adult ADHD. The study enrolled 50 adults, and median AISRS symptom-score reductions reached 14.00 points at the 20 milligram dose and 19.00 points at the 50 milligram dose, according to Alkermes.

The company said the phase 2 study was enrolling about 312 adults, with the first participant dosed in September 2026 and data expected in 2027. The study was exploratory and was not designed or powered to detect statistically significant differences, a qualification that keeps the early signal separate from proof of efficacy.

What does the pipeline signal mean?

Stifel's USD 63.00 target was paired with a Buy rating, while the same report cited the coming Vibrance-3 phase 2 readout in idiopathic hypersomnia and enrollment in Brilliance phase 3 trials for narcolepsy. The report also listed TD Cowen at USD 58.00 and Goldman Sachs at USD 50.00, showing a wide spread in analyst expectations rather than a single market view.

Alkermes also reported USD 496.01 million of revenue in the second quarter of 2026, versus a USD 458.98 million consensus estimate, according to Investing.com. The comparison gives the pipeline story a commercial backdrop, although clinical development remains the larger valuation driver.

Three recent company milestones

On September 10, 2026, Alkermes opened its ninth Pathways Research Awards program with grants of up to USD 100,000 per project, according to Alkermes. On September 16, 2026, the board expanded from 10 to 11 directors and approved a USD 600,000 initial equity award for Anne C. Whitaker, as reported in an SEC filing carried by StockTitan. On September 21, 2026, the company published the 50-patient ALKS 7290 phase 1b update.

Upcoming dates include October 28

Alkermes' next earnings date is October 28, 2026, according to MarketBeat. The Pathways program's first submission period ends October 16, 2026, and its full application phase begins November 15, 2026, according to Alkermes.

Stock remains below its yearly high

The Lang & Schwarz quote stood at EUR 36.67 in trading on October 8, 2026 at 3:38 p.m. CEST, minus 0.95 percent versus the EUR 37.02 prior close at Lang & Schwarz on October 7, 2026. On Nasdaq, the primary listing, the finance quote showed USD 41.24 at 9:48 a.m. EDT on October 8, 2026, against a 52-week range of USD 27.00 to USD 55.67.

The further course of trading is shown by the continuously updated real-time quote of Alkermes stock.